[1]
|
K. L. Barry, M. F. Fleming, J. R. Greenley, S. Kropp, P. Widlak, “Characteristics of persons with severe mental illness and substance abuse in rural areas,” Psychiatric Services, Vol. 47, No. 1, January 1996, pp. 88-90.
|
[2]
|
I. L. Fowler, V. J. Carr, N. T. Carter, T. J. HLewin, H“HPatterns of current and lifetime substance use in schizophrenia,”H Schizophrenia Bulletin, Vol. 24, No. 3, 1998, pp. 443-455.
|
[3]
|
R. G. McCreadie, Scottish Comorbidity Study Group, “HUse of drugs, alcohol and tobacco by people with schizophrenia: case-control study,”H The British Journal of Psychiatry, Vol. 181, October 2002, pp. 321-325.
|
[4]
|
K. T. Mueser, P. Nishith, J. I. Tracy, J. DeGirolamo, M. Molinaro, “Expectations and motives for substance use in schizophrenia,” Schizophrenia Bulletin, Vol. 21, No. 3, 1995, pp. 367-378.
|
[5]
|
L. Arseneault, M. Cannon, R. Poulton, R. HMurray, HA. HCaspi,H T.E. HMoffitt, H“Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study,” British Medical Journal, Vol. 325, No. 7374, November 2002, pp. 1212-1213.
|
[6]
|
C. HCurran,H N. HByrappa, HA. HMcBride, H“Stimulant psychosis: systematic review,” The HBritish Journal of PsychiatryH, Vol. 185, September 2004, pp. 196-204.
|
[7]
|
E. HJacobs, HD. HFujii, HJ. HSchiffman, HI. HBello,H “An exploratory analysis of neurocognition in methamphetamine-in- duced psychotic disorder and paranoid schizophrenia,” Cognitive and Behavioral Neurology, Vol. 21, No.2, June 2008, pp. 98-103.
|
[8]
|
J. Addington, D. Addington, “Patterns, predictors and impact of substance use in early psychosis: A longitudinal study,” Acta Psychiatrica Scandinavica, Vol. 115, No. 4, April 2007, pp. 304-309.
|
[9]
|
J. H. HBarnett, HU. HWerners, HS. M. HSecher, HK. E. HHill, HR. HBrazil, HK. HMasson, HD. E. HPernetH, J. B. HKirkbride,H G. K. HMurrayH, E. T. HBullmore,H P. B. HJones, H“Substance use in a population-based clinic sample of people with first-epi- sode psychosis,” The HBritish Journal of PsychiatryH, Vol. 190, June 2007, pp. 515-520.
|
[10]
|
R. HCantwell, HJ. HBrewin, HC. HGlazebrook, HT. HDalkin, HR. HFox, HI. HMedley, HG. Harrison, “Prevalence of substance misuse in first-episode psychosis,” The HBritish Journal of PsychiatryH, Vol. 174, February 1999, pp. 150-153.
|
[11]
|
S. I. A. Rahim, M. S. Abumadini, M. S. Khalil, T. Musa, “Long-term outcome of treated addiction in Saudi Arabia: predictors of relapse in 10 year follow-up,” The Arab Journal of Psychiatry, Vol.16, No. 2, November 2005, pp. 86-97.
|
[12]
|
M. S. AbuMadini, S. I. A. Rahim, M. A. Al-Zahrani, A. O. AL-Johi, (2008). “Two decades of treatment seeking for substance use disorders in Saudi Arabia: trends and patterns in a rehabilitation facility in Dammam,” Drug and Alcohol Dependence, Vol. 97, No. 3, October 2008, pp. 231-236.
|
[13]
|
Department of Health and Human Services, “Mandatory Guidelines for Federal Workplace Drug Testing Programs: Final guidelines notice,” Federal Register, Vol. 53, 1989, pp.11969-11989.
|
[14]
|
A. HJablensky, HJ. HMcGrath, HH. HHerrman, HD. HCastle, HO. HGureje, HM. HEvans, H“Psychotic disorders in urban areas: an overview of the study on low prevalence disorders,” The Australian and New Zealand of Psychiatry, Vol. 34, No. 2, April 2000, pp. 221-236.
|
[15]
|
S. R. Kay, L. A. Opler, J. P. Lindenmayer, “Reliability and validity of the positive and negative syndrome scale for schizophrenics,” Psychiatry Research, Vol. 23, No. 1, January 1988, pp. 99-110.
|
[16]
|
S. R. Kay, L. A. Opler, J. P. Lindenmayer, “The positive and negative syndrome scale (PANSS): rationale and standardization,” The British Journal of Psychiatry (Sup- pl), Vol. 7, November 1989, pp. 59-67.
|
[17]
|
A. W. Loranger, N. Sartorius, A. Andreoli, P. Berger, P. Buchheim, S. M. Channabasavanna, B. Coid, A. Dahl, R. F. Diekstra, B. Ferguson, et al, “The personality disorder examination: a preliminary report,” Archives of General Psychiatry, Vol. 51, No. 3, March 1994, pp. 215-224. A. W. HLoranger, HM. F.
|
[18]
|
HLenzenweger, HA. F. HGartner, HV. L. HSusman, HJ. HHerzig, HG. K. HZammit, J. D. Gartner , R. C. Abrams, R. C. Young,H “Trait-state artifacts and the diagnosis of personality disorders,” Archives of General Psychiatry, Vol. 48, No.8, August 1991, pp. 720-728.
|
[19]
|
S. Van Mastrigt, J. Addington, D. Addington, D. “Substance misuse at presentation to an early psychosis program,” Social Psychiatry and Psychiatry Epidemiology, Vol. 39, No. 1, January 2004, pp. 69-72.
|
[20]
|
D. Wade, S. Harrigan, J. Edwards, P. M. Burgess, G. Whelan, P. D. McGorry, “Course of substance misuse and daily tobacco use in first episode psychosis,” Schizo- phrenia Research, Vol. 81, No. 2-3, January 2006, pp. 145-150.
|
[21]
|
V. M. HGonzalez, HC. M. HBradizza, HP. C. HVincent, HP. R. HStasiewicz, HN. D. HPaas, H“Do individuals with a severe mental illness experience alcohol and drug-related problems? A test of the supersensitivity hypothesis,” Addictive Behaviors, Vol. 32, No. 3, March 2007, pp. 477-490.
|
[22]
|
D. HHarris, HS. L. HBatki, H“Stimulant psychosis: symptom profile and acute clinical course,” HThe American Journal on Addiction, Vol.9, No.3, Winter 2000, pp.H 28-37.
|
[23]
|
N. Chivite-Matthews, A. Richardson, J. O’Shea, J. Bec- ker, N. Owen, S. Roe, et al, “Drug misuse declared: Findings from 2003/2004 British crime survey,” Home office statistical survey, 2005.
|
[24]
|
C. L. HCaton, HR. E. HDrake, HD. S. HHasin, HB. HDominguez, HP. E. HShrout, HS. HSamet, HB. Schanzer, “Differences between early phase primary psychotic disorders with concurrent substance use and substance-induced psychoses,” Archives of General Psychiatry, Vol. 62, No. 2, February 2005, pp. 137-145.
|
[25]
|
M. J. HSchiller, HM. HShumway, HS. L. HBatki, H“Patterns of substance use among patients in an urban psychiatric emergency service,” HPsychiatric Services, Vol. 51, No.1, January 2000, pp. 113-115.
|
[26]
|
M. HLambert,H P. HConus, HD. I. HLubman, HD. HWade, HH. HYuen, HS. HMoritz, D. Naber, B. G. Schimmelmann, H“The impact of substance use disorders on clinical outcome in 643 patients with first episode psychosis,” Acta Psychiatrica Scandinavics, Vol. 112, No.2, August 2005, pp. 141-148.
|
[27]
|
L. HHides, HS. M. HCotton, HG. HBerger, HJ. HGleeson, HC. HO’Donnell, HT. HProffitt, HP. D. McGorry, D. I. Lubman, “The reliability and validity of the alcohol, smoking and substance involvement screening test (ASSIST) in first episode psychosis,” Addictive Behaviors, Vol. 34, No. 10, October 2009, pp. 821-25.
|
[28]
|
C. L. HCaton, HR. E. HDrake, HD. S. HHasin, HB. HDominguez, HP. E. HShrout, HS. HSamet, HB. Schanzer, “Differences between early phase primary psychotic disorders with concurrent substance use and substance-induced psychoses,” Archives of General Psychiatry, Vol. 62, No. 2, February 2005, pp. 137-145.
|
[29]
|
J. M. Brown, G. R. Hanson, A. E. Fleckenstein, “Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants,” J Pharmacol Exp Ther, Vol 286, No. 3, March 2001, pp. 762-767.
|
[30]
|
A. M. HBarr,H W. J. HPanenka, HG. W. HMacEwan, HA. E. HThornton, HD. J. HLang, HW. G. HHoner, W. GH., T. Lecomte, “The need for speed: an update on methamphetamine addiction,” J Psychiatry Neurosci, Vol. 31, No.5, September 2006, pp. 301-313.
|
[31]
|
C. K. HChen, HS. K. HLin, HP. C. HSham, HD. HBall, HE. W. HLoh, HC. C. HHsiao, HY. L. HChiangH, S. C. HReeH, C. H. HLeeH, R. M. HMurray,H “Premorbid characteristics and co-morbidity of methamphetamine users with and without psychosis,” Psychological Medicine, Vol. 33, No. 8, November 2003, pp. 1407-1414.
|
[32]
|
C. C. Cruickshank, K. R. Dyer, (2009). “A review of the clinical pharmacology of methamphetamine,” Addiction, Vol. 104, No. 7, July 2009, pp. 1085-1099.
|
[33]
|
M. J. Schiller, M. Shumway, S. L. Batki, “Utility of Routine Drug Screening in a Psychiatric Emergency Setting,” Psychiatric Servoces, Vol. 51, No. 4, April 2000, pp. 474- 478.
|
[34]
|
R. McKetin, J. McLaren, D. Lubman, L. Hides, “The prevalence of psychotic symptoms among methamphetamine users,” Addiction, Vol. 101, No. 4, April 2000, pp. 1473-1478.
|
[35]
|
A. HBaker, HS. HBucci, HT. J. HLewin, HR. HRichmond, HV. J. HCarr, H“Comparisons between psychosis samples with different patterns of substance use recruited for clinical and epidemiological studies,” Psychiatry Research, Vol.134, No. 3, April 2005, pp. 241-250.
|
[36]
|
H. C. HMargolese, HL. HMalchy, HJ. C. HNegrete, HR. HTempier, HK. H. HGill, H“Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences,” Schizophrenia Research, Vol. 67, No. (2-3), April 2004, pp. 157-66.
|
[37]
|
A. HDavies, HM. A. HAdena, HN. A. HKeks, HS. V. HCatts, HT. HLambert, HI. HSchweitzer, H “Risperidone versus haloperidol: Meta-analysis of efficacy and safety,” HClinical The- rapeutics, HVol.20, No.1, January-February 1998, pp. 58- 71.
|
[38]
|
HCarlson, C. DH., HCavazzoni, P. AH., HBerg, P. HH., HWei, HH., HBeasley, C. MH., HKane, J. MH. (2003). An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. HJ Clin PsychiatryH, 64, 898-906.
|
[39]
|
B. M. HSchanzer, HM. B. HFirst, HB. HDominguez, HD. S. HHasin, HC. L. HCaton, H“Diagnosing psychotic disorders in the emergency department in the context of substance use,” HPsychiatric ServHices, Vol. 57, No. 10, October 2006, pp. 1468-1473.
|
[40]
|
D. S. Bell, “The experimental reproduction of amphetamine psychosis,” Archives of General Psychiatry, Vol. 29, No.1, July 1973, pp. 35-40.
|
[41]
|
H. Ujiki, M. Sato, “Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis,” Annals of the New York Academy of Sciences, Vol. 1025, October 2004, pp. 279-87.
|
[42]
|
M. A, HTest,H L. S. HWallisch, HD. J. HAllnessH, K. HRipp, H“Substance use in young adults with schizophrenic disorders,” HSchizophrenia BullHetin Vol.15, No.3, 1989, pp. 465-4765.
|
[43]
|
C. J. Van Dongen, Smoking and persistent mental illness: an exploratory study,” Journal of Psychosocial. Nursing and Mental Health Services, Vol. 37, No. 11, November 1999, pp. 26-34.
|
[44]
|
M. HSrisurapanont, HR. HAli, HJ. HMarsden, HA. HSunga, HK. HWada, HM. HMonteiro, H“Psychotic symptoms in methamphetamine psychotic in-patients,” The International Journal of Neuropsychopharmacology, Vol. 6, No. 4, December 2003, pp. 347-352.
|
[45]
|
D. HHarris, HS.L. HBatki, H“Stimulant psychosis: symptom profile and acute clinical course,” The American Journal on Addiction, Vol. 9, No. 1, Winter 2000, pp. 28-37.
|
[46]
|
I. I. Solano, M. G. DeChavez, “Premorbid personality disorders in schizophrenia,” Schizophrenia Research, Vol. 44, No. 2, August 2000, pp.137-144.
|
[47]
|
D. Lichtermann, E. Karbe, W. Maier, “The genetic epidemiology of schizophrenia and of schizophrenia spectrum disorders,” European Archives of Psychiatry and Neuroscience, Vol. 250, No.6, 2000, pp. 304-310.
|
[48]
|
M. S. HKeshavan, HH. S. HDuggal, HG. HVeeragandham, HN. M. HMcLaughlin, HD. M. HMontrose, HG. L. HHaas, HN. R. Schooler, “Personality dimensions in first-episode psychoses,” The American Journal of Psychiatry, Vol. 162, No. 1, January 2005, pp. 102-109.
|
[49]
|
J. C. Maxwell, “Emerging research on methamphetamine,” Current Opinion in Psychiatry, Vol. 18, No. 3, May 2005, pp. 235-242.
|
[50]
|
S. D. Gray, Fatovich, D. M. McCoubrie, D. L., Daly, F. F. “Amphetamine-related presentations to an inner-city tertiary emergency department: a prospective evaluation,” The Medical Journal of Australia, Vol. 186, No. 7, April 2007, pp. 336-339.
|
[51]
|
L. HHidesH, S. M. HCotton,H G. HBergerH, J. HGleesonH, C. HO’DonnellH, T. HProffittH, P. D. HMcGorryH, D. I. HLubmanH, “The reliability and validity of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in first-episode psychosis,” HAddictive Behaviors, Vol. 34, No. 10, October 2009, pp. 821-25.
|